Xiamen University

Anhui New Star Pharmaceutical Development Co., Ltd.

Zhixiang He

Xianming Deng

Wei Peng Huang

Ting Zhang

Zhiyu Hu

Li Li

Qingyan Xu

Xihuan Sun

Jingfang Zhang

Yan Liu

Baoding Zhang

Xiaoyang Li

Yun Chen

Xinrui Wu

Dawang Zhou

Lanfen Chen

Fuqin Fan

A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.

Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof

The present invention relates to compounds (I) capable of inhibiting the Mst1/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutical composition comprising the compounds in the preparation of drugs for prompting repair and regeneration of tissues and organs, prompting stem cell proliferation and somatic cell dedifferentiation, immunosuppression, and preventing or treating diseases related to nervous disorders and local ischemia.

Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof

Growing community of inventors

Xiamen, China

Zhixiang He